Zevra Therapeutics (ZVRA) Invested Capital (2014 - 2026)

Zevra Therapeutics' (ZVRA) quarterly Invested Capital came in at $37.7 million in Q4 2023, up 5419.77% on a QoQ basis from $683000.0 in Q1 2021.

Analysis

Zevra Therapeutics (ZVRA) Invested Capital (2014 - 2026) Analysis & Trends

Zevra Therapeutics (ZVRA) has 5 years of Invested Capital data on file, last reported at $37.7 million in Q4 2023.

Quarterly Invested Capital changed N/A year-over-year to $37.7 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $37.7 million (changed N/A YoY) and the FY2023 annual result came in at $37.7 million, changed N/A from the prior year.
Invested Capital improved to $37.7 million in Q4 2023, from $683000.0 in the prior quarter.
In the past five years, Invested Capital ranged from a high of $37.7 million in Q4 2023 to a low of $390000.0 in Q4 2020.
A 3-year average of $12.9 million and a median of $683000.0 in 2021 frame the typical range for Invested Capital.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	Zevra Therapeutics	734.60 Mn	513.03 Mn	38.18 Mn	217.65 Mn

Historic Data

Download Data